Tarsus Pharmaceuticals (TARS) Total Liabilities (2019 - 2026)

Tarsus Pharmaceuticals' Total Liabilities history runs 8 years deep, the most recent figure standing at $232.2 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 46.68% year-over-year to $232.2 million in Q1 2026; TTM through Mar 2026 was $232.2 million, a 46.68% increase from a year earlier, with the FY2025 full-year figure at $218.7 million, up 43.47% from the prior year.
• Total Liabilities improved to $232.2 million in Q1 2026 per TARS's latest filing, from $218.7 million in the prior quarter.
• Across five years, Total Liabilities topped out at $232.2 million in Q1 2026 and bottomed at $31.3 million in Q2 2022.
• The 5-year median for Total Liabilities is $74.1 million (2024), against an average of $105.6 million.
• Across the five-year window, Total Liabilities grew 17.11% in 2023 and jumped 202.44% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $35.0 million in 2022, then soared by 95.93% to $68.5 million in 2023, then surged by 122.56% to $152.5 million in 2024, then soared by 43.47% to $218.7 million in 2025, then advanced by 6.15% to $232.2 million in 2026.
• Per Business Quant, the three latest TARS Total Liabilities figures stand at $232.2 million (Q1 2026), $218.7 million (Q4 2025), and $199.5 million (Q3 2025).